GenScript Says AI Drug Discovery Business Doubled in First Half

Aug 19, 2026
GenScript reported first half revenue of about US$404.2 million, up 27.3% year over year, and said its AI enabled drug discovery business doubled from a year earlier.
GenScript Says AI Drug Discovery Business Doubled in First Half

GenScript Biotech Corporation announced in a press release first half revenue of about US$404.2 million on a comparable basis, up 27.3% year over year. Adjusted net profit rose 203.3% to about US$62.5 million.

The company said its AI enabled drug discovery business doubled year over year and continued rapid growth for a third consecutive half year reporting period. GenScript cited demand from AI focused biotechnology companies and pharmaceutical innovators.

GenScript said Gene-to-Protein accounted for about 66% of GenScript Life Science Group revenue. The platform supports discovery, experimental validation, early development, and production support.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.